Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Let’s just say you wake up one morning in The Handmaid’s Tale universe, stuck inside the color-coded hellscape that is Gilead ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The ultraconservative dictatorship in which the series based on Margaret Atwood’s novel is set is becoming less and less unthinkable ...

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The health crisis has spilled into South Africa’s universities and research hubs. Institutions that once hosted major NIH- ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...